Cellectar prototype outperforms free paclitaxel
August 2016

MADISON, Wis.—Biotechnology company Cellectar Biosciences Inc. has reported that the results of a preliminary tumor-targeting study revealed that CLR 1602, its prototype paclitaxel chemotherapeutic conjugate, may be up to 30 times more tumor-selective than free paclitaxel. The in-vivo study—which was designed to evaluate the pharmacokinetics, absorption and distribution after a single intravenous administration of CLR 1602 vs. free paclitaxel mice—showed that tumor uptake of CLR 1602’s paclitaxel payload increased by more than 30-fold over free paclitaxel. In addition, CLR 1602’s payload demonstrated an extended plasma half-life as well, with prolonged retention even at 96 hours, compared to free paclitaxel, which was cleared from plasma within 24 hours. Cellectar presented a poster on these results at the recent 35th National Medicinal Chemistry Symposium in Chicago in late June.

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.